Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α‐Synuclein

• Published in: Movement disorders Vol. 38; no. 3; pp. 378 - 384
• Main Authors: Jensen, Poul Henning, Schlossmacher, Michael G., Stefanis, Leonidas
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.03.2023; Wiley Subscription Services, Inc
• Subjects: aggregation; alpha-Synuclein; Animal models; Animals; Antibodies; Biomarkers; Clinical trials; Humans; Immunization; Immunization (passive); Immunotherapy; Movement disorders; Neurodegeneration; Neurodegenerative diseases; Neuroprotection; oligomers; Parkinson Disease - drug therapy; Parkinson's disease; Synuclein; synucleinopathy; Therapeutic targets; therapeutics; Treatment Outcome; synucleinopathy; therapeutics; aggregation; oligomers; immunotherapy
• ISSN: 0885-3185; 1531-8257
• DOI: 10.1002/mds.29318

Two recent, high‐profile manuscripts reported negative results with two parallel approaches of passive immunization targeting α‐synuclein in a population of patients with early Parkinson's disease (PD). These phase II studies failed to show a bona fide disease‐modifying neuroprotective effect on PD progression, despite the evidence that these antibodies effectively bind native α‐synuclein in human serum. Here, we discuss the possible reasons that could help explain the lack of clinical efficacy. In particular, we highlight (1) the wealth of evidence supporting the notion of α‐synuclein as a valid therapeutic target; (2) the lack of evidence of target engagement in the aforementioned studies, especially of the elusive oligomeric species, the likely culprits in disease pathogenesis and/or its propagation; (3) the limitations, especially in terms of timing passive immunization, of preclinical models, where the same α‐synuclein antibodies succeeded in mitigating disease manifestations; (4) the consideration of possibly intervening at an even earlier stage of disease in future trials; and (5) the multitude of strategies beyond passive immunization that could be used to combat α‐synuclein‐mediated neurodegeneration, if in the end the current approach is not fruitful. Overall, our perception is that converging developments in the field, among them novel bioassays and biomarkers, improved cellular and animal models and objective measurements of motor activities integrated into clinical trials, if further optimized, will gradually move the momentum of the field forward. This, to better test the concept of whether α‐synuclein‐targeting therapies can indeed deliver the ”holy grail” of neuroprotection to the benefit of the PD community. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.